Since its launch in late October 2017, Stryker Spine Division's Tritanium C Anterior Cervical Cage has been implanted by 311 surgeons in more than 1,770 procedures across the U.S. Stryker has sold more than 3,188 Tritanium C implants.
Here are four things to know.
1. The 3D-printed interbody fusion cage intended for use in the cervical spine is constructed from Stryker's proprietary Tritanium Technology, a highly porous titanium material designed for bone in-growth and biological fixation.
2. Tritanium's porous structure is intended to create a favorable environment for cell attachment and proliferation. The Tritanium material may be able to wick or retain fluid.
3. The proprietary technology enables the creation of porous structures designed to mimic cancellous bone in pore size, porosity level and pore interconnectivity. Tritanium Cages feature an open central graft window and lateral windows to help reduce cage stiffness of and minimize subsidence. The large graft window is designed to allow for bone graft containment.
4. The Tritanium C Anterior Cervical Cage received 510(k) clearance from the FDA and September 2017 and was introduced during the North American Spine Society conference from Oct. 25–28, 2017. The full commercial launch occurred on Dec. 10, 2017.
Here are the Tritanium C Anterior Cervical Cage indications for use.
More articles on surface technology:
10 things to know about Titan Spine
3 observations on spine implant technology from Dr. Christian Zimmerman
CTL Medical receives FDA clearance for ACIF cage with TiCro technology: 4 key notes